---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-24-000985"
form_type: "8-K"
ticker: "AEMD"
cik: "0000882291"
company_name: "AETHLON MEDICAL INC"
filed_at: "2024-02-14T23:59:59+00:00"
generated_at: "2026-06-06T02:54:00.310146+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Aethlon Medical Q3 net loss widens to $3.6M; expenses up 25% on CEO separation costs

## Summary
- Net loss of $3.6M for fiscal Q3 ended Dec 31, 2023, vs $2.8M a year ago.
- Operating expenses $3.6M (+25% YoY), driven by $873K in former CEO separation costs.
- Cash balance $8.0M as of Dec 31, 2023; company focusing on expense reduction.
- Received DCGI clearance in India for phase 1 trial of Hemopurifier in solid tumors.
- In vitro binding study results inconclusive; engaging third-party labs for independent assays.

## SEC filing metadata
- accession: 0001683168-24-000985
- form_type: 8-K
- ticker: AEMD
- cik: 0000882291
- company_name: AETHLON MEDICAL INC
- filed_at: 2024-02-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/882291/000168316824000985/0001683168-24-000985-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/882291/000168316824000985/aethlon_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-24-000985
- JSON: https://secwatch.observer/filing/0001683168-24-000985.json
- Plain text: https://secwatch.observer/filing/0001683168-24-000985.txt

## Key facts
- Earnings Releases
  AETHLON MEDICAL INC reported fiscal third quarter ended December 31, 2023 results: net income $3.6 million.
  - Period: fiscal third quarter ended December 31, 2023
  - Net income: $3.6 million
  - Result: reported results
  source text: On February 14, 2024, Aethlon Medical, Inc. issued a press release announcing its financial results for the quarter ended December 31, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/882291/000168316824000985/0001683168-24-000985-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.